Stuart Jon Spechler

List of Publications by Year in Descending Order

191 papers	14,492 citations	50 h-index	120 g-index
209 ext. papers	16,635 ext. citations	10.6 avg, IF	6.69 L-index

#	Paper	IF	Citations
191	Spastic secondary contractile patterns identified by FLIP panometry in symptomatic patients with unremarkable high-resolution manometry.. *Neurogastroenterology and Motility*, **2022**, e14321	4	
190	Timing of Resumption of Anticoagulation After Polypectomy and Frequency of Post-procedural Complications: A Post-hoc Analysis.. *Digestive Diseases and Sciences*, **2022**, 1	4	0
189	International consensus recommendations for eosinophilic gastrointestinal disease nomenclature.. *Clinical Gastroenterology and Hepatology*, **2022**,	6.9	3
188	ACG Clinical Guideline for the Diagnosis and Management of Gastroesophageal Reflux Disease. *American Journal of Gastroenterology*, **2021**,	0.7	34
187	Implications of Recent Revelations from Basic and Clinical Studies of Barrett Esophagus for Screening and Surveillance Strategies. *Foregut*, **2021**, 1, 86-92		
186	Functional Anatomy and Physiology of Swallowing and Esophageal Motility **2021**, 59-96		1
185	Diagnosis and Treatment of Esophageal Chest Pain **2021**, 18-37		
184	Pulmonary Complications of Gastroesophageal Reflux Disease **2021**, 567-580		
183	Ambulatory Monitoring for Reflux **2021**, 188-207		0
182	Behavioral Treatment of Oropharyngeal and Esophageal Disorders **2021**, 492-509		
181	The Esophagus **2021**, 53-58		
180	Pathophysiology of Gastroesophageal Reflux Disease **2021**, 376-393		
179	Special Endoscopic Imaging and Optical Techniques for Evaluating the Esophagus **2021**, 148-154		
178	Challenges in the Understanding and Application of Antireflux Surgery for GERD **2021**, 591-601		
177	Esophageal Disease in Older Patients **2021**, 804-853		
176	Medical Management of Gastroesophageal Reflux Disease **2021**, 428-443		1
175	Tumors of the Esophagus **2021**, 633-650		

174 Pathophysiology of Gastroesophageal Reflux Disease **2021**, 358-375

173 Role of Histology and Cytology in Esophageal Diseases **2021**, 218-246

172 New Surgical Treatments for GERD **2021**, 602-623

171 High-Resolution Manometry and Esophageal Pressure Topography **2021**, 155-171 0

170 Esophagitis in the Immunocompromised Host **2021**, 736-756

169 Esophageal Diverticula **2021**, 304-311

168 Esophageal Webs and Rings **2021**, 294-303

167 Refractory Heartburn **2021**, 444-464

166 Surgery for Esophageal Motor Disorders **2021**, 278-293

165 Disorders Causing Oropharyngeal Dysphagia **2021**, 38-52

164 Histologic Study of the Esophagogastric Junction of Organ Donors Reveals Novel Glandular Structures in Normal Esophageal and Gastric Mucosae. *Clinical and Translational Gastroenterology*, **2021**, 12, e00346 4.2 0

163 Endoscopic Treatment of Esophageal Cancer **2021**, 651-660

162 Endoscopic Therapies for GERD **2021**, 465-491

161 Clinical Spectrum and Diagnosis of GERD Phenotypes **2021**, 333-346

160 Pediatric Gastroesophageal Reflux Disease **2021**, 581-590

159 Symptom Overview and Quality of Life **2021**, 1-17

158 Hiatus Hernia and Gastroesophageal Reflux Disease **2021**, 347-357

157 New Diagnostic Tests for GERD **2021**, 208-217

156	Non-Achalasia Esophageal Motility Abnormalities **2021**, 265-277		
155	Obesity and Gastroesophageal Reflux Disease **2021**, 624-632		2
154	Esophageal Involvement in Systemic Diseases **2021**, 312-332		
153	Duodenogastroesophageal Reflux **2021**, 394-418		
152	ENT Complaints in GERD **2021**, 554-566		
151	Cutaneous Diseases of the Esophagus **2021**, 789-803		
150	Medication-Induced Esophageal Injury **2021**, 728-735		
149	Surgical Treatment for Esophageal Cancer **2021**, 661-677		
148	Foreign Bodies **2021**, 713-727		
147	Radiology of the Pharynx and Esophagus **2021**, 97-147		0
146	Esophageal Testing Using Multichannel Intraluminal Impedance **2021**, 172-187		
145	Helicobacter pylori and GERD **2021**, 419-427		
144	Caustic Injuries of the Esophagus **2021**, 757-768		
143	Rupture and Perforation of the Esophagus **2021**, 769-788		
142	Esophageal Strictures **2021**, 532-553		
141	In Esophageal Squamous Cells From Eosinophilic Esophagitis Patients, Th2 Cytokines Increase Eotaxin-3 Secretion Through Effects on Intracellular Calcium and a Non-Gastric Proton Pump. *Gastroenterology*, **2021**, 160, 2072-2088.e6	13.3	8
140	Lower esophageal sphincter muscle of patients with achalasia exhibits profound mast cell degranulation. *Neurogastroenterology and Motility*, **2021**, 33, e14055	4	8
139	Mast cell effects on esophageal smooth muscle and their potential role in eosinophilic esophagitis and achalasia. *American Journal of Physiology - Renal Physiology*, **2021**, 320, G319-G327	5.1	2

138	Advances in Biomarkers for Risk Stratification in Barrett's Esophagus. *Gastrointestinal Endoscopy Clinics of North America*, **2021**, 31, 105-115	3.3	2
137	Invited response to letter to the editor by Tustumi et al. *Neurogastroenterology and Motility*, **2021**, 33, e14114	4	
136	Evaluation and Management of Patients with PPI-Refractory Heartburn. *Current Treatment Options in Gastroenterology*, **2021**, 19, 134-152	2.5	
135	Refractory Gastroesophageal Reflux Disease and Functional Heartburn. *Gastrointestinal Endoscopy Clinics of North America*, **2020**, 30, 343-359	3.3	9
134	Evaluation and Treatment of Patients with Persistent Reflux Symptoms Despite Proton Pump Inhibitor Treatment. *Gastroenterology Clinics of North America*, **2020**, 49, 437-450	4.4	5
133	In Barrett's epithelial cells, weakly acidic bile salt solutions cause oxidative DNA damage with response and repair mediated by p38. *American Journal of Physiology - Renal Physiology*, **2020**, 318, G464-G478	5.1	4
132	Mucosal pathogenesis in gastro-esophageal reflux disease. *Neurogastroenterology and Motility*, **2020**, 32, e14022	4	11
131	Screening for Barrett's oesophagus: are we looking for the right thing?. *Gut*, **2020**,	19.2	1
130	Efficacy of Prophylactic Hemoclips in Prevention of Delayed Post-Polypectomy Bleeding in Patients With Large Colonic Polyps. *Gastroenterology*, **2019**, 157, 967-976.e1	13.3	44
129	Aberrant p53 Immunostaining in Barrett's Esophagus Predicts Neoplastic Progression: Systematic Review and Meta-Analyses. *Digestive Diseases and Sciences*, **2019**, 64, 1089-1097	4	19
128	Eosinophilic esophagitis: novel concepts regarding pathogenesis and clinical manifestations. *Journal of Gastroenterology*, **2019**, 54, 837-844	6.9	11
127	Pathogenesis and Cells of Origin of Barrett's Esophagus. *Gastroenterology*, **2019**, 157, 349-364.e1	13.3	61
126	Randomized Trial of Medical versus Surgical Treatment for Refractory Heartburn. *New England Journal of Medicine*, **2019**, 381, 1513-1523	59.2	85
125	Endoscopic Evaluation of the Esophagus and Endoscopic Ultrasonography of the Esophagus **2019**, 85-114		
124	Gastroesophageal Reflux Disease and Eosinophilic Esophagitis. *Gastroenterology and Hepatology*, **2019**, 15, 111-113	0.7	2
123	Barrett's Esophagus **2019**, 21-34		
122	American registry of pathology expert opinions: Evaluating patients with eosinophilic esophagitis: Practice points for endoscopists and pathologists. *Annals of Diagnostic Pathology*, **2019**, 43, 151418	2.2	0
121	Proton Pump Inhibitors: What the Internist Needs to Know. *Medical Clinics of North America*, **2019**, 103, 1-14	7	10

120	Acidic Bile Salts Induce Epithelial to Mesenchymal Transition via VEGF Signaling in Non-Neoplastic Barrett's Cells. *Gastroenterology*, **2019**, 156, 130-144.e10	13.3	34
119	Unique Clinical Features of Los Angeles Grade D Esophagitis Suggest That Factors Other Than Gastroesophageal Reflux Contribute to its Pathogenesis. *Journal of Clinical Gastroenterology*, **2019**, 53, 9-14	3	5
118	New Eosinophilic Esophagitis Concepts Call for Change in Proton Pump Inhibitor Management Before Diagnostic Endoscopy. *Gastroenterology*, **2018**, 154, 1217-1221.e3	13.3	12
117	Cardiac Metaplasia: Follow, Treat, or Ignore?. *Digestive Diseases and Sciences*, **2018**, 63, 2052-2058	4	11
116	Management options for patients with GERD and persistent symptoms on proton pump inhibitors: recommendations from an expert panel. *American Journal of Gastroenterology*, **2018**, 113, 980-986	0.7	50
115	Obtaining adequate lamina propria for subepithelial fibrosis evaluation in pediatric eosinophilic esophagitis. *Gastrointestinal Endoscopy*, **2018**, 87, 1207-1214.e3	5.2	13
114	Incidence of Colorectal Cancer and Extracolonic Cancers in Veteran Patients With Inflammatory Bowel Disease. *Inflammatory Bowel Diseases*, **2018**, 24, 617-623	4.5	22
113	Oesophagus: A new candidate for the progenitor cell of Barrett metaplasia. *Nature Reviews Gastroenterology and Hepatology*, **2018**, 15, 7-8	24.2	1
112	New Screening Techniques in Barrett's Esophagus: Great Ideas or Great Practice?. *Gastroenterology*, **2018**, 154, 1594-1601	13.3	33
111	Columnar-Lined Esophagus Develops via Wound Repair in a Surgical Model of Reflux Esophagitis. *Cellular and Molecular Gastroenterology and Hepatology*, **2018**, 6, 389-404	7.9	9
110	Can Eosinophilic Esophagitis Cause Achalasia and Other Esophageal Motility Disorders?. *American Journal of Gastroenterology*, **2018**, 113, 1594-1599	0.7	38
109	Updated International Consensus Diagnostic Criteria for Eosinophilic Esophagitis: Proceedings of the AGREE Conference. *Gastroenterology*, **2018**, 155, 1022-1033.e10	13.3	367
108	Speculation as to why the Frequency of Eosinophilic Esophagitis Is Increasing. *Current Gastroenterology Reports*, **2018**, 20, 26	5	11
107	Radiofrequency Ablation of Barrett's Esophagus Reduces Esophageal Adenocarcinoma Incidence and Mortality in a Comparative Modeling Analysis. *Clinical Gastroenterology and Hepatology*, **2017**, 15, 1471-1474	6.9	18
106	Hypoxia-inducible factor-2 plays a role in mediating oesophagitis in GORD. *Gut*, **2017**, 66, 1542-1554	19.2	26
105	A Comparison of the Rate of Gastrointestinal Bleeding in Patients Taking Non-Vitamin K Antagonist Oral Anticoagulants or Warfarin. *American Journal of Gastroenterology*, **2017**, 112, 734-739	0.7	28
104	Clarifying misunderstandings and misinterpretations about proton pump inhibitor-responsive oesophageal eosinophilia. *Gut*, **2017**, 66, 1173-1174	19.2	3
103	Barrett's metaplasia develops from cellular reprograming of esophageal squamous epithelium due to gastroesophageal reflux. *American Journal of Physiology - Renal Physiology*, **2017**, 312, G615-G622	5.1	18

102	White Paper AGA: Drug Development for Eosinophilic Esophagitis. *Clinical Gastroenterology and Hepatology*, **2017**, 15, 1173-1183	6.9	24
101	A new paradigm for GERD pathogenesis. Not acid injury, but cytokine-mediated inflammation driven by HIF-2α a potential role for targeting HIF-2α to prevent and treat reflux esophagitis. *Current Opinion in Pharmacology*, **2017**, 37, 93-99	5.1	23
100	NOD-Like Receptor Protein 3 Inflammasome Priming and Activation in Barrett's Epithelial Cells. *Cellular and Molecular Gastroenterology and Hepatology*, **2016**, 2, 439-453	7.9	27
99	In oesophageal squamous cells, nitric oxide causes S-nitrosylation of Akt and blocks SOX2 (sex determining region Y-box 2) expression. *Gut*, **2016**, 65, 1416-26	19.2	14
98	Proton pump inhibitor-responsive oesophageal eosinophilia: an entity challenging current diagnostic criteria for eosinophilic oesophagitis. *Gut*, **2016**, 65, 524-31	19.2	219
97	JAK-STAT6 Pathway Inhibitors Block Eotaxin-3 Secretion by Epithelial Cells and Fibroblasts from Esophageal Eosinophilia Patients: Promising Agents to Improve Inflammation and Prevent Fibrosis in EoE. *PLoS ONE*, **2016**, 11, e0157376	3.7	38
96	How to Build the Trust of Your Referring Physicians **2016**, 133-139		
95	Association of Acute Gastroesophageal Reflux Disease With Esophageal Histologic Changes. *JAMA - Journal of the American Medical Association*, **2016**, 315, 2104-12	27.4	120
94	Mitochondrial STAT3 contributes to transformation of Barrett's epithelial cells that express oncogenic Ras in a p53-independent fashion. *American Journal of Physiology - Renal Physiology*, **2015**, 309, G146-61	5.1	18
93	Diagnosis of Esophageal Motility Disorders: Esophageal Pressure Topography vs. Conventional Line Tracing. *American Journal of Gastroenterology*, **2015**, 110, 967-77; quiz 978	0.7	73
92	Cardiac mucosa: the heart of the problem. *Gut*, **2015**, 64, 1673-4	19.2	5
91	Barrett's esophagus: definition and diagnosis **2015**, 15-24		
90	The Effect of Proton Pump Inhibitors on Barrett's Esophagus. *Gastroenterology Clinics of North America*, **2015**, 44, 415-24	4.4	16
89	Development and characterization of a surgical mouse model of reflux esophagitis and Barrett's esophagus. *Journal of Gastrointestinal Surgery*, **2014**, 18, 234-40; discussion 240-1	3.3	13
88	Autocrine VEGF signaling promotes proliferation of neoplastic Barrett's epithelial cells through a PLC-dependent pathway. *Gastroenterology*, **2014**, 146, 461-72.e6	13.3	38
87	In Barrett's esophagus patients and Barrett's cell lines, ursodeoxycholic acid increases antioxidant expression and prevents DNA damage by bile acids. *American Journal of Physiology - Renal Physiology*, **2014**, 307, G129-39	5.1	42
86	Use of hemoclips and other measures to prevent bleeding during colonoscopy by gastroenterologists in Veterans Affairs hospitals. *American Journal of Gastroenterology*, **2014**, 109, 288-90	9.7	6
85	Barrett's esophagus. *New England Journal of Medicine*, **2014**, 371, 836-45	59.2	345

84	Use of proton pump inhibitors and subsequent risk of celiac disease. *Digestive and Liver Disease*, **2014**, 46, 36-40	3.3	37
83	Eosinophilic esophagitis: interactions with gastroesophageal reflux disease. *Gastroenterology Clinics of North America*, **2014**, 43, 243-56	4.4	35
82	In oesophageal squamous cells exposed to acidic bile salt medium, omeprazole inhibits IL-8 expression through effects on nuclear factor-B and activator protein-1. *Gut*, **2014**, 63, 1042-52	19.2	53
81	Controversies in Barrett esophagus. *Mayo Clinic Proceedings*, **2014**, 89, 973-84	6.4	14
80	Does Barrett's esophagus regress after surgery (or proton pump inhibitors)?. *Digestive Diseases*, **2014**, 32, 156-63	3.2	13
79	Hedgehog signaling regulates FOXA2 in esophageal embryogenesis and Barrett's metaplasia. *Journal of Clinical Investigation*, **2014**, 124, 3767-80	15.9	66
78	Proton pump inhibitors decrease eotaxin-3 expression in the proximal esophagus of children with esophageal eosinophilia. *PLoS ONE*, **2014**, 9, e101391	3.7	34
77	Barrett esophagus and risk of esophageal cancer: a clinical review. *JAMA - Journal of the American Medical Association*, **2013**, 310, 627-36	27.4	192
76	Barrett's esophagus: the American perspective. *Digestive Diseases*, **2013**, 31, 10-6	3.2	11
75	Omeprazole blocks eotaxin-3 expression by oesophageal squamous cells from patients with eosinophilic oesophagitis and GORD. *Gut*, **2013**, 62, 824-32	19.2	226
74	Barrett Esophagus **2013**, 723-738		2
73	Endoscopic Evaluation of the Esophagus **2013**, 101-111		
72	Consensus statements for management of Barrett's dysplasia and early-stage esophageal adenocarcinoma, based on a Delphi process. *Gastroenterology*, **2012**, 143, 336-46	13.3	305
71	Omeprazole blocks STAT6 binding to the eotaxin-3 promoter in eosinophilic esophagitis cells. *PLoS ONE*, **2012**, 7, e50037	3.7	156
70	Tissue remodeling in eosinophilic esophagitis. *American Journal of Physiology - Renal Physiology*, **2012**, 303, G1175-87	5.1	76
69	Relationship of Eosinophilic Esophagitis to Gastroesophageal Reflux **2012**, 135-146		
68	Barrett's esophagus: Clinical issues. *Gastrointestinal Endoscopy Clinics of North America*, **2011**, 21, 1-7	3.3	9
67	American Gastroenterological Association medical position statement on the management of Barrett's esophagus. *Gastroenterology*, **2011**, 140, 1084-91	13.3	751

66	American Gastroenterological Association technical review on the management of Barrett's esophagus. *Gastroenterology*, **2011**, 140, e18-52; quiz e13	13.3	798
65	Durability of radiofrequency ablation in Barrett's esophagus with dysplasia. *Gastroenterology*, **2011**, 141, 460-8	13.3	367
64	Eosinophilic esophagitis: updated consensus recommendations for children and adults. *Journal of Allergy and Clinical Immunology*, **2011**, 128, 3-20.e6; quiz 21-2	11.5	1502
63	Deoxycholic acid causes DNA damage while inducing apoptotic resistance through NF-B activation in benign Barrett's epithelial cells. *American Journal of Physiology - Renal Physiology*, **2011**, 301, G278-86	5.1	90
62	Buried metaplasia after endoscopic ablation of Barrett's esophagus: a systematic review. *American Journal of Gastroenterology*, **2011**, 106, 1899-908; quiz 1909	0.7	139
61	Cancer-related inflammation and Barrett's carcinogenesis: interleukin-6 and STAT3 mediate apoptotic resistance in transformed Barrett's cells. *American Journal of Physiology - Renal Physiology*, **2011**, 300, G454-60	5.1	49
60	History, molecular mechanisms, and endoscopic treatment of Barrett's esophagus. *Gastroenterology*, **2010**, 138, 854-69	13.3	148
59	A systematic review of the risk of perforation during esophageal dilation for patients with eosinophilic esophagitis. *Digestive Diseases and Sciences*, **2010**, 55, 1512-5	4	83
58	Might the use of acid-suppressive medications predispose to the development of eosinophilic esophagitis?. *American Journal of Gastroenterology*, **2009**, 104, 1897-902	0.7	82
57	Management of nondysplastic Barrett's esophagus: where are we now?. *American Journal of Gastroenterology*, **2009**, 104, 805-8	0.7	21
56	Radiofrequency ablation in Barrett's esophagus with dysplasia. *New England Journal of Medicine*, **2009**, 360, 2277-88	59.2	1097
55	In benign Barrett's epithelial cells, acid exposure generates reactive oxygen species that cause DNA double-strand breaks. *Cancer Research*, **2009**, 69, 9083-9	10.1	74
54	Potential anti-inflammatory effects of proton pump inhibitors: a review and discussion of the clinical implications. *Digestive Diseases and Sciences*, **2009**, 54, 2312-7	4	221
53	Gastroesophageal reflux might cause esophagitis through a cytokine-mediated mechanism rather than caustic acid injury. *Gastroenterology*, **2009**, 137, 1776-84	13.3	261
52	Surgery for gastroesophageal reflux disease: esophageal impedance to progress?. *Clinical Gastroenterology and Hepatology*, **2009**, 7, 1264-5	6.9	21
51	Endoscopic therapy in Barrett's esophagus: when and how?. *Surgical Oncology Clinics of North America*, **2009**, 18, 509-21	2.7	5
50	Intestinal differentiation in metaplastic, nongoblet columnar epithelium in the esophagus. *American Journal of Surgical Pathology*, **2009**, 33, 1006-15	6.7	136
49	Unlike esophageal squamous cells, Barrett's epithelial cells resist apoptosis by activating the nuclear factor-kappaB pathway. *Cancer Research*, **2009**, 69, 672-7	10.1	40

48	Bone marrow progenitor cells contribute to esophageal regeneration and metaplasia in a rat model of Barrett's esophagus. *Ecological Management and Restoration*, **2008**, 21, 43-50	3	121
47	Stem cells in Barrett's esophagus: HALOs or horns?. *Gastrointestinal Endoscopy*, **2008**, 68, 41-3	5.2	12
46	Integrated approach to treatment of children and adults with eosinophilic esophagitis. *Gastrointestinal Endoscopy Clinics of North America*, **2008**, 18, 195-217; xi	3.3	31
45	Acid, bile, and CDX: the ABCs of making Barrett's metaplasia. *American Journal of Physiology - Renal Physiology*, **2008**, 295, G211-8	5.1	140
44	Screening and surveillance for Barrett esophagus. *Current GERD Reports*, **2007**, 1, 179-184		0
43	Thoughts on the complex relationship between gastroesophageal reflux disease and eosinophilic esophagitis. *American Journal of Gastroenterology*, **2007**, 102, 1301-6	0.7	270
42	Banding without resection (endoscopic mucosal ligation) as a novel approach for the ablation of short-segment Barrett's epithelium: results of a pilot study. *American Journal of Gastroenterology*, **2007**, 102, 1640-5	0.7	11
41	GERD is associated with shortened telomeres in the squamous epithelium of the distal esophagus. *American Journal of Physiology - Renal Physiology*, **2007**, 293, G19-24	5.1	13
40	Screening and surveillance for Barrett's esophagus-an unresolved dilemma. *Nature Reviews Gastroenterology & Hepatology*, **2007**, 4, 470-1		18
39	High-frequency probe ultrasonography has limited accuracy for detecting invasive adenocarcinoma in patients with Barrett's esophagus and high-grade dysplasia or intramucosal carcinoma: a case series. *American Journal of Gastroenterology*, **2006**, 101, 1773-9	0.7	45
38	Thermal ablation of Barrett's esophagus: a heated debate. *American Journal of Gastroenterology*, **2006**, 101, 1770-2	0.7	24
37	Gastric and esophageal pH in patients with Barrett's esophagus treated with three esomeprazole dosages: a randomized, double-blind, crossover trial. *American Journal of Gastroenterology*, **2006**, 101, 1964-71	0.7	56
36	Concepts in the prevention of adenocarcinoma of the distal esophagus and proximal stomach. *Ca-A Cancer Journal for Clinicians*, **2005**, 55, 334-51	220.7	63
35	Barrett's esophagus: a molecular perspective. *Current Gastroenterology Reports*, **2005**, 7, 177-81	5	15
34	Risk of community-acquired pneumonia after acid-suppressive drugs. *Nature Reviews Gastroenterology & Hepatology*, **2005**, 2, 72-3		1
33	Fundoplication and the risk of esophageal cancer in gastroesophageal reflux disease: a Veterans Affairs cohort study. *American Journal of Gastroenterology*, **2005**, 100, 1002-8	0.7	67
32	Dysplasia in Barrett's esophagus: limitations of current management strategies. *American Journal of Gastroenterology*, **2005**, 100, 927-35	0.7	99
31	Acid increases proliferation via ERK and p38 MAPK-mediated increases in cyclooxygenase-2 in Barrett's adenocarcinoma cells. *American Journal of Physiology - Renal Physiology*, **2004**, 287, G743-8	5.1	58

30	What is the long-term effect of high-dose versus standard-dose omeprazole in patients with dyspepsia?. *Nature Reviews Gastroenterology & Hepatology*, **2004**, 1, 12-3		
29	Re-examination of the cost-effectiveness of surgical versus medical therapy in patients with gastroesophageal reflux disease: the value of long-term data collection. *American Journal of Gastroenterology*, **2004**, 99, 1023-8	0.7	30
28	The management of patients who have "failed" antireflux surgery. *American Journal of Gastroenterology*, **2004**, 99, 552-61	0.7	54
27	Intestinal metaplasia at the gastroesophageal junction. *Gastroenterology*, **2004**, 126, 567-75	13.3	60
26	A critical review of the diagnosis and management of Barrett's esophagus: the AGA Chicago Workshop. *Gastroenterology*, **2004**, 127, 310-30	13.3	521
25	Intestinal metaplasia at the gastroesophageal junction: Barrett's, bacteria, and biomarkers. *American Journal of Gastroenterology*, **2003**, 98, 759-62	0.7	24
24	The natural history of dysplasia and cancer in esophagitis and Barrett esophagus. *Journal of Clinical Gastroenterology*, **2003**, 36, S2-5; discussion S26-8	3	28
23	Clinical manifestations and esophageal complications of GERD. *American Journal of the Medical Sciences*, **2003**, 326, 279-84	2.2	30
22	Esophageal complications of gastroesophageal reflux disease: presentation, diagnosis, management, and outcomes. *Clinical Cornerstone*, **2003**, 5, 41-8; discussion 49-50		16
21	Medical or invasive therapy for GERD: an acidulous analysis. *Clinical Gastroenterology and Hepatology*, **2003**, 1, 81-8	6.9	7
20	A 59-year-old woman with gastroesophageal reflux disease and Barrett esophagus. *JAMA - Journal of the American Medical Association*, **2003**, 289, 466-75	27.4	3
19	Clinical practice. Barrett's Esophagus. *New England Journal of Medicine*, **2002**, 346, 836-42	59.2	509
18	Acid exposure activates the mitogen-activated protein kinase pathways in Barrett's esophagus. *Gastroenterology*, **2002**, 122, 299-307	13.3	183
17	Barrett's esophagus and esophageal adenocarcinoma: pathogenesis, diagnosis, and therapy. *Medical Clinics of North America*, **2002**, 86, 1423-45, vii	7	50
16	Hallmarks of cancer progression in Barrett's oesophagus. *Lancet, The*, **2002**, 360, 1587-9	40	125
15	Columnar-lined esophagus. Definitions. *Chest Surgery Clinics of North America*, **2002**, 12, 1-13, vii		19
14	Long-term outcome of medical and surgical therapies for gastroesophageal reflux disease: follow-up of a randomized controlled trial. *JAMA - Journal of the American Medical Association*, **2001**, 285, 2331-8	27.4	669
13	Disputing dysplasia. *Gastroenterology*, **2001**, 120, 1864-8	13.3	31

12	The role of gastric carditis in metaplasia and neoplasia at the gastroesophageal junction. *Gastroenterology*, **1999**, 117, 218-28	13.3	149
11	AGA technical review on treatment of patients with dysphagia caused by benign disorders of the distal esophagus. *Gastroenterology*, **1999**, 117, 233-54	13.3	158
10	The columnar lined oesophagus: a riddle wrapped in a mystery inside an enigma. *Gut*, **1997**, 41, 710-1	19.2	29
9	Prevalence and significance of pancreatic acinar metaplasia at the gastroesophageal junction. *American Journal of Surgical Pathology*, **1996**, 20, 1507-10	6.7	70
8	Development for and results of the use of a gastroesophageal reflux disease activity index as an outcome variable in a clinical trial. VA Cooperative Study Group on Gastroesophageal Reflux Disease (GERD). *Contemporary Clinical Trials*, **1994**, 15, 335-48		37
7	Diagnostic inconsistencies in Barrett's esophagus. *Gastroenterology*, **1994**, 107, 945-949	13.3	143
6	Laser photoablation of Barrett's epithelium: burning issues about burning tissues. *Gastroenterology* , **1993**, 104, 1855-8	13.3	22
5	Detection by scanning electron microscopy of a distinctive esophageal surface cell at the junction of squamous and Barrett's epithelium. *Digestive Diseases and Sciences*, **1993**, 38, 97-108	4	79
4	Comparison of medical and surgical therapy for complicated gastroesophageal reflux disease in veterans. The Department of Veterans Affairs Gastroesophageal Reflux Disease Study Group. *New England Journal of Medicine*, **1992**, 326, 786-92	59.2	491
3	Barrett's esophagus. *New England Journal of Medicine*, **1986**, 315, 362-71	59.2	686
2	Barrett Esophagus and Esophageal Adenocarcinoma826-848		
1	Barrett Esophagus and Esophageal Adenocarcinoma949-974		